ALR Technologies, Inc. (OTCBB:ALRT) recently updated a movie/Power Point which is a presentation from a “Randomized Controlled Trial” showing the effect of internet therapeutic intervention on HbA1c (hemoglobin A1c) levels in patients with Type 2 diabetes treated with insulin. The six-month study was conducted by Tildesley et al. and concludes that the use of an IBGMS (Internet Based Glucose Monitoring System) is an effective method of improving glucose control compared to standard care.

The A1c level is the gold standard in determination of chronic glycemic control in people with diabetes. It is important to keep the A1c level as low as possible to control risks associated with diabetes. As the final slide points out, According to Centers of Disease Control and Prevention,

In general, every percentage drop in A1c blood test results (e.g. from 8% to 7%) can reduce the risk of microvascular complications (eye, kidney and nerve disease) by 40%.

Products such as ALR Technologies’ Health-e-Connect System and Welldoc’s self-named platform are designed to encourage patient compliance and monitoring of glucose levels in manners shown to be effective by this trial.

Begin your due diligence and keep up to date instantly with ALR Technologies’ developments here.

Alrt randomized controlled trial

View more presentations from ALR Technologies

ALR Technologies (ALRT) Stock Quote and News:

---

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated twenty thousand dollars per month for three months of consultation and journalism services and to manage a comprehensive investor relations/awareness program by ALR Technologies. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.